RxDoctor Payments DataLook up a doctor →

Raymond Phillips

Naples, FLNPI 1437155231

Payments from drug & device makers

$1,831,152in general payments, 2019–2025

Across 1,062 payments — averaging $1724.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$584K
  • Takeda Pharmaceuticals U.S.A., Inc.$470K
  • Gilead$267K
  • Boehringer Ingelheim International GmbH$155K
  • AstraZeneca$77K
  • Vectivbio AG$65K
  • plus $211K from 21 others
$67,467in research payments, 2019–2025

Across 17 payments — averaging $3968.63 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Gilead$27K
  • AbbVie$27K
  • Celltrion, Inc.$9K
  • Takeda Pharmaceuticals U.S.A., Inc.$4K
  • Sanofi US Services Inc.$319

What the payments were for

  • Consulting fees$1,47035%
  • Food & beverage$2,44858%
  • Education$3047%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →